Get the Stockscreener App
13.57
5.76%
-0.83
Regenxbio Inc stock is traded at $13.57, with a volume of 1.33M.
It is down -5.76% in the last 24 hours and up +11.14% over the past month.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
See More
Previous Close:
$14.40
Open:
$14.65
24h Volume:
1.33M
Relative Volume:
2.05
Market Cap:
$686.96M
Revenue:
$89.04M
Net Income/Loss:
$-241.08M
P/E Ratio:
-2.5798
EPS:
-5.26
Net Cash Flow:
$-194.72M
1W Performance:
-4.17%
1M Performance:
+11.14%
6M Performance:
+57.42%
1Y Performance:
+72.65%
1-Day Range:
$12.91
$14.65
1-Week Range:
$12.91
$14.65
52-Week Range:
$5.035
$15.41
Regenxbio Inc Stock (RGNX) Company Profile
Name
Regenxbio Inc
Sector
Industry
Phone
240-552-8181
Address
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Compare RGNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
13.57 | 728.97M | 89.04M | -241.08M | -194.72M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-25 | Downgrade | Goldman | Buy → Neutral |
| Feb-07-25 | Resumed | Raymond James | Outperform |
| Nov-15-24 | Resumed | Morgan Stanley | Overweight |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Jun-07-24 | Initiated | Goldman | Buy |
| Mar-11-24 | Initiated | H.C. Wainwright | Buy |
| Mar-08-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-06-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-21-24 | Resumed | Raymond James | Outperform |
| Nov-01-23 | Initiated | Stifel | Buy |
| Jun-02-23 | Initiated | Robert W. Baird | Outperform |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Dec-15-21 | Initiated | Wedbush | Neutral |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Jan-06-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-20-19 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Jun-18-19 | Reiterated | Chardan Capital Markets | Buy |
| Jun-14-19 | Resumed | Raymond James | Outperform |
| Jun-05-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-25-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-05-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-17-18 | Reiterated | Chardan Capital Markets | Buy |
| Nov-08-18 | Reiterated | BofA/Merrill | Neutral |
| Aug-08-18 | Reiterated | Chardan Capital Markets | Buy |
| Jul-23-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-10-18 | Reiterated | Chardan Capital Markets | Buy |
| May-09-18 | Reiterated | Barclays | Overweight |
| Apr-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-13-18 | Initiated | Mizuho | Neutral |
| Nov-09-17 | Resumed | Morgan Stanley | Overweight |
View All
Regenxbio Inc Stock (RGNX) Latest News
REGENXBIO updates Phase 1/2 data for Duchenne candidate - MSN
Trading the Move, Not the Narrative: (RGNX) Edition - Stock Traders Daily
Prospects for Regenxbio’s clemidsogene lanparvovec approval in Hunter syndrome - The Pharma Letter
REGENXBIO (NASDAQ:RGNX) Trading Down 3.8%Here's Why - MarketBeat
REGENXBIO Inc. (NASDAQ:RGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement - simplywall.st
Behavioral Patterns of RGNX and Institutional Flows - Stock Traders Daily
REGENXBIO (NASDAQ:RGNX) Hits New 1-Year HighWhat's Next? - MarketBeat
Assenagon Asset Management S.A. Purchases 132,942 Shares of REGENXBIO Inc. $RGNX - MarketBeat
REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Stifel raises Regenxbio stock price target to $45 on upcoming catalysts By Investing.com - Investing.com Australia
Stifel Maintains REGENXBIO (RGNX) Buy Recommendation - Nasdaq
REGENXBIO (NASDAQ:RGNX) Shares Up 9.2%What's Next? - MarketBeat
What hedge fund activity signals for REGENXBIO Inc. stockCPI Data & Breakout Confirmation Trade Signals - DonanımHaber
Stifel Raises Price Target for Regenxbio (RGNX) to $45 | RGNX St - GuruFocus
Stifel raises Regenxbio stock price target to $45 on upcoming catalysts - Investing.com Nigeria
Decliners Report: How interest rate cuts could boost REGENXBIO Inc. stockQuarterly Profit Review & Risk Adjusted Buy/Sell Alerts - Улправда
Why REGENXBIO Inc. stock is recommended by analystsTreasury Yields & Detailed Earnings Play Alerts - DonanımHaber
Squarepoint Ops LLC Boosts Holdings in REGENXBIO Inc. $RGNX - MarketBeat
Will REGENXBIO Inc. stock reach Wall Street targetsForecast Cut & Daily Profit Focused Stock Screening - DonanımHaber
Is REGENXBIO Inc. stock a smart buy before Fed meetingJuly 2025 Trends & Scalable Portfolio Growth Ideas - ulpravda.ru
How interest rate cuts could boost REGENXBIO Inc. stockPortfolio Gains Report & Consistent Return Investment Signals - Улправда
Is REGENXBIO Inc. stock a contrarian buy2025 Risk Factors & Fast Entry Momentum Trade Alerts - Улправда
REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference - The AI Journal
Leerink Partners Maintains REGENXBIO (RGNX) Outperform Recommendation - Nasdaq
Leerink Partners raises Regenxbio stock price target to $20 on DMD opportunity By Investing.com - Investing.com South Africa
Regenxbio (RGNX): Leerink Partners Raises Price Target to USD 20 - GuruFocus
Leerink Partners raises Regenxbio stock price target to $20 on DMD opportunity - Investing.com Nigeria
REGENXBIO (NASDAQ:RGNX) Reaches New 1-Year HighWhat's Next? - MarketBeat
RegenXBio’s gene therapy study for Hunter syndrome: A potential game-changer - MSN
RegenXBio’s Gene Therapy Study for Hunter Syndrome: A Potential Game-Changer - TipRanks
REGENXBIO (NASDAQ:RGNX) Stock Price Up 5.2%Time to Buy? - MarketBeat
(RGNX) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
REGENXBIO (NASDAQ:RGNX) Reaches New 52-Week HighShould You Buy? - MarketBeat
Wet Age-Related Macular Degeneration Market Growth - openPR.com
Voss Capital LP Boosts Stock Holdings in REGENXBIO Inc. $RGNX - MarketBeat
REGENXBIO Inc. $RGNX is 22NW LP's 5th Largest Position - MarketBeat
Regenxbio Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
Will REGENXBIO Inc. (RB0) stock announce special dividend2025 Major Catalysts & Real-Time Volume Spike Alerts - Newser
What insider trading reveals about REGENXBIO Inc. stockJuly 2025 Snapshot & Smart Allocation Stock Tips - Newser
Why global investors buy REGENXBIO Inc. (RB0) stock2025 Market WrapUp & Safe Capital Allocation Plans - Newser
Will REGENXBIO Inc. (RB0) stock profit from fiscal stimulus2025 Big Picture & Safe Entry Zone Identification - Newser
Can REGENXBIO Inc. stock resist market sell offsQuarterly Profit Review & Technical Pattern Based Signals - Newser
Is REGENXBIO Inc. stock resilient to inflationGold Moves & Fast Exit Strategy with Risk Control - Newser
JPMorgan Chase & Co. Sells 512,318 Shares of REGENXBIO Inc. $RGNX - MarketBeat
Will REGENXBIO Inc. (RB0) stock see valuation expansionWeekly Trade Analysis & Reliable Trade Execution Plans - Newser
REGENXBIO announces royalty monetization agreement for up to $250M - MSN
Regenxbio Inc Stock (RGNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):